Nucleolin

Nucleolin Molekülinformation

Englischer Name	Nucleolin	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	4	Target-Alias	NCL，Nucleolin，Protein C23，Nsr1，C23
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Nucleolin
Target-Alias	NCL，Nucleolin，Protein C23，Nsr1，C23
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	4
Höchste Forschungs- und Entwicklungsphase	Approved

Nucleolin Produktliste

Attribut
Protein (3)
Produktbibliothek
Online (3)
Spezies
Human (2)Mouse (1)
Etikett
Mouse IgG Fc Tag (2)Fc Tag (1)
Marker
Unconjugated (3)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
HOT NUL-H5253	Human	HEK293	Human Nucleolin / NCL Protein, Fc Tag	In den Warenkorb legen
NUL-H5254	Human	HEK293	Human Nucleolin / NCL Protein, Mouse IgG2a Fc Tag	In den Warenkorb legen
NUL-M5253	Mouse	HEK293	Mouse Nucleolin / NCL Protein, Mouse IgG2a Fc Tag	In den Warenkorb legen

Gesamtmenge3

Nucleolin Molekülhintergrund

Nucleolin is the major nucleolar protein of growing eukaryotic cells. It is found associated with intranucleolar chromatin and pre-ribosomal particles. It induces chromatin decondensation by binding to histone H1. It is thought to play a role in pre-rRNA transcription and ribosome assembly. May play a role in the process of transcriptional elongation. Binds RNA oligonucleotides with 5'-UUAGGG-3' repeats more tightly than the telomeric single-stranded DNA 5'-TTAGGG-3' repeats.

Nucleolin Molekülalias

Nucleolin,NCL,Protein C23

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
IPP-204106	N6L; Nucant-6L; IPP-204106; IPP-204106N; poyplexed IPP-204106	Phase 2 Clinical	Immupharma Plc	Neoplasms; Solid tumours	Details
AS-1411	AGRO-100; GR-026-B; AS-1411; ACT-GRO-777	Phase 2 Clinical	Antisoma, University Of Alabama At Birmingham, University Of Louisville	Neoplasms; Solid tumours	Details
Pegylated recombinant human endostatin (Tsinghua University)	M-2ES; CRB-0401	Phase 1 Clinical	Beijing Proji Pharmaceutical Technology Co Ltd, Beijing Protgen Biotechnology Development Co Ltd, Tsinghua University	Carcinoma, Non-Small-Cell Lung; Neoplasms; Pancreatic Neoplasms; Solid tumours	Details
APTA-16	APTA-16; SJP1604	Phase 1 Clinical	Aptabio Therapeutics Inc	Leukemia, Myeloid, Acute; Liver Neoplasms; Myelodysplastic Syndromes	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Recombinant human endostatin (Simcere)	YH-16	Approved	Jiangsu Simcere Pharmaceutical Co Ltd	Endostar, 恩度, Endu	Mainland China	Carcinoma, Non-Small-Cell Lung	Shandong Xiansheng Zaiming Biopharmaceutical Co Ltd	2005-09-12	Ascites; Brain metastases; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Head and Neck Neoplasms; Nasopharyngeal Carcinoma; Osteosarcoma; Pleural Effusion, Malignant	Details